Prophylactic Use of Metformin to Decrease the Incidence of Breast Cancer in High Risk, Predisposed Women
Download Full Text (429 KB)
• Breast cancer is one of the most common types of cancer in American women and is the second leading cause of mortality.
• In 2015, 234,190 new diagnoses were made and 40,730 deaths from breast cancer.
• Along with a thorough history from the patient, there are also several risk assessment models that should be utilized, such as the common Gail-2 model.
• Any women with a significant family history should also be educated on genetic counseling and/or testing to detect a BRCA1 or 2 mutation.
• Numerous individuals who are positive for this gene elect to undergo prophylactic treatment, such as an oophorectomy, mastectomy or the use of Tamoxifen, or an aromatase inhibitor, also called selective estrogen receptor modulators or SERMS.
• These medications reduce the amount of estrogen in the body, have been shown to reduce cases of breast cancer, but also come with side effects, such as an increased risk of endometrial cancer, cataracts or venous thrombolytic events.
Physician Assistant Studies
Master of Physician Assistant Studies (MPAS)
Breast Neoplasms -- epidemiology; Breast Neoplasms -- prevention & control; Diabetes Mellitus, Type 2 -- drug therapy; Hypoglycemic Agents -- therapeutic use; Metformin -- therapeutic use
Neoplasms | Oncology
Dahl, Aly, "Prophylactic Use of Metformin to Decrease the Incidence of Breast Cancer in High Risk, Predisposed Women" (2017). Physician Assistant Scholarly Project Posters. 35.